“ Int’l Big Pharma” Sterilizing & Discriminating Against American Women
“ALSO VIEW THE MULTIPLE “HAND ME DOWN MEGA-MERGER DRUGS” –
American women, pharmaceutical “Eugenics Theory” tactics harming, sterilizing and killing millions of American women. Please ask yourselves how can a pharmaceutical company who discriminates against women, truly care about womens reproductive health? You’ll view below, contradictory occurrences.
American women please view below information for your personal protection! Also please do your own personal due diligence before taking drugs prescribed. This is for your health, safety and well-being please try to utilize home remedies or natural health products, like grandma or your mother taught you!
The combination of contraceptive drugs Drospirenone and ethinyl estradiol has been associated with a number of Drospirenone side effects. Bayer, the manufacturer of oral contraceptives containing theDrospirenone drug is now facing thousands of Drospirenone lawsuits. Or BERLEX, SCHERING
Drospirenone and Heart Attack. Drospirenone (similar to other medicines typically used as diuretics such as Spironolactone), combined with ethinyl estradiol, has shown an increase in the blood’s potassium levels. This increase can lead to hyperkalemia, which can result in cardiac arrest. Hyperkalemia often has no symptoms, and is often detected after serious heart conditions have already occurred.
Drospirenone and Venous Thromboembolism (VTE). Drospirenone has also been associated with venous thromboembolism (VTE)—blood clots that form within a vein. A number of studies, most recently published in the BMJ(October 2011), suggest that women on these pills (listed above) containing one of the newer types of progestogen hormone (drospirenone, desogestrel or gestodene) have double the risk of VTE than women on pills containing an older progestogen (levonorgestrel).
Drospirenone and Deep Vein Thrombosis (DVT).Drospirenone has also been linked to deep vein thrombosis (DVT), which is a blood clot that forms in a deep vein, and pulmonary embolism—blood clots in the lungs.
New research published in the Canadian Medical Association Journal (November, 2011) involving about 330,000 women in Israel found that women taking birth-control pills containing the drospirenone were as much as 65 per cent more likely to develop venous thromboembolism than women taking older generations
of the pill Drospirenone and Gallbladder disease.It is also associated with gallbladder disease, particularly in young women.
Washington, DC: The Food and Drug Administration (FDA) announced today that it is revising the labels fordrospirenone-containingbirth control pills, warning of the higher associated risk for blot clots.
The change results from a newly completed review by the FDA of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Based on this review, the FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills.
Drospirenone is a synthetic version of the female hormone, progesterone, also referred to as a progestin. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills.
Drospirenone lawsuits against Bayer—both involving side effects and deceptive marketing of Yaz and Yasmin–allege that the drug company:
Underplayed the risks associated with the products and overstated their approved uses in an effort to mislead users of Yaz and Yasmin into believing that the drugs were safe.
Failed to properly research the medication.
Failed to recall the drug after post-marketing reports demonstrated that the risk of potentially life-threatening side effects of Yasmin and Yaz outweighed potential benefits that could be achieved via other available oral contraceptives.
AMS Transvaginal Mesh injury includes debilitating and potentially life-long complications, which has led to AMS legal complaints. Many AMS transvaginal mesh lawsuits have been filed by women who were implanted with AMS transvaginal mesh, claiming the AMS mesh is defective. American Medical Systems (AMS), based in Minnesota, is a major manufacturer of transvaginal meshmedical devices, which are support systems designed to correct pelvic organ prolapse, (POP) and stress urinary incontinence (SUI).
Johnson & Johnson is the global leader in prolapse mesh, followed by American Medical Systems, Boston Scientific, and Bard. As more women are implanted with TVM, complaints are on the rise: Between 2008 and 2010, the FDA received 1,503 reports of injuries or malfunction, a fivefold increase from 2005 to 2007.
In 2010, about 300,000 women in the US had pelvic organ prolapse (POP) surgeries, including more than 70,000 who received vaginal meshes. Approximately185,000 women underwent procedures in which mesh was implanted vaginally to treat stress urinary incontinence (SUI).
The FDA has received a number of adverse reports regarding AMS transvaginal mesh. These reports have resulted in a number of lawsuits filed against the company by women who may have been implanted with the following AMS mesh:
AMS Apogee Vault Suspension System
AMS Elevate Prolapse Repair System
AMS Monarc Sling System
AMS Perigee System
AMS Sparc Sling System
$54.5M Settlement Proposed for Some Transvaginal Mesh Lawsuits Endo Health Solutions Inc, which acquired American Medical Systems Inc., (AMS), the maker of the vaginal-mesh devices, which include the Perigee, Apogee and Elevate implants, said in a statement that is set to resolve an undisclosed number of the vaginal mesh personal injury lawsuits. However, AMs is facing over 5,000 such lawsuits, which have been consolidated: the first lawsuit set to go to court in December 2013.
New Mirena Lawsuit Claims Woman Sustained Permanent Injuries During “Unethical” Clinical Trial Testing Off-Label Use of Mirena IUD
Beyaz Birth Control – The US Food and Drug Administration (FDA) has issued a warning that women using birth control similar to Beyaz birth controlcould be at increased risk of drospirenone side effects. According to the FDA and researchers, drugs such as Beyaz birth control, which contain drospirenone are associated with an increased risk of blood clots. The FDA is now investigating potential Beyaz side effectsand other drospirenone reactions. Although lawsuits have been filed against other birth control makers, so far no Beyaz lawsuitshave been filed.
On September 26, 2011, the FDA issued a warning that the use of birth control medications that contain drospirenonecould potentially be linked to an increased risk of blood clots. The announcement came after the FDA completed a review of two studies from 2011 that evaluated the risk of blood clots in women who use medications that contain drospirenone. Furthermore, the FDA has funded a study that evaluates the risk of blood clots in women who use hormonal birth control products. Preliminary results of that study suggest that women who take a birth control pill containing drospirenone has approximately 1.5 times the risk of blood clots of women who use other hormonal contraceptives.
Beyaz side effectsare similar to those of Yasmin and Yaz, and even though some lawsuits name all three birth control pills, Bayer’s Annual Report 2013 does not mention Beyaz in its Legal Risks Section. The Annual Report discusses other Beyaz lawsuit risks, but not those alleging side effects from Beyaz birth control
NuvaRing lawsuitshave been filed alleging women suffered serious side effects as a result of using the NuvaRing birth control. Among the reported side effects is an increased risk of NuvaRing strokeand NuvaRing blood clots, some of which have allegedly resulted in the deaths of young women.
NuvaRing Birth Control – Same as the Mirena-Iud – NuvaRing is a birth control product that is placed near the cervix and releases a dose of synthetic hormones—etongestrel (a progestin) and ethinyl estradiol (estrogen)—over a 21-day period. The vaginal ring is taken out after the 3-week period and then left out for one week to allow for menstruation. Following that week, a new ring is inserted.
NuvaRing works by suppressing ovulation and also by thickening cervical mucus to help ensure fertilization cannot occur. NuvaRing was approved by the US Food and Drug Administration (FDA) for use in 2001.
NuvaRing, along with other third- and fourth-generation contraceptives, has been linked to an increased risk of blood clots. Two studies, published in 2009 in the British Medical Journal, found that third- and fourth-generation contraceptives were associated with almost twice the risk of a blood clot, compared with second-generation contraceptives. If a blood clot comes loose and travels to the patient’s brain, this can cause a stroke, which can have serious and fatal repercussions for the patient. Patients who survive their stroke may wind up with lifelong injuries, including paralysis.
Merck Settles Nuvaring Litigation Commenced by Attorney Jason T. Brown for 100 Million Dollars – http://www.lawyersandsettlements.com/articles/nuvaring-blood-clot-death-removed/nuvaring-lawsuit-blood-clots-side-10-19506.html#.UzOzPPldXww
NuvaRing: Lawsuits Allege Merck Downplayed Risks
Serious complications have been associated with transvaginal surgical mesh , which is used to treat pelvic organ prolapse (POP) and Stress Urinary Incontinence (SUI). Lawsuits have been filed against C.R. Bard, the manufacturer of Bard Avaulta mesh , alleging the Bard Avaulta System is defective. Avaulta Mesh An increasing nu…
An increasing number of complaints have been reported to the FDA against the makers of transvaginal mesh(TVM) medical devices. Bard Avaulta TVM problems range from pain during sex to erosion of vaginal tissue and infection to even death.
Pelvic Organ Prolapse (POP)
Bard Avaulta transvaginal mesh (TVM) is used to treat pelvic organ prolapse (POP), which occurs when organs, including the uterus or bowel, drop against the wall of the vagina. In some cases, synthetic vaginal mesh such as Avaulta is implanted to support the muscle. In other cases, surgeons stitch the connective tissue in the vaginal wall back together. Bard surgical mesh is also used to treat Stress Urinary Incontinence (SUI).
Currently product liability lawsuits are being filed against a number of transvaginal mesh manufacturers, including Bard, claiming that the vaginal slings were negligently designed, causing pain and other complications.
Lawsuits filed against C.R. Bard, the maker of Bard Avaulta Anterior and Posterior Biosynthetic Support System, also known as Bard Avaulta Mesh or Bard Avaulta System, allege serious Avaulta meshcomplications
A number of pelvic organ prolapse (POP) patients with the Bard Avualta vaginal mesh claim that defects in the design of the synthetic mesh caused them to suffer severe injuries and complications after surgery. Further, lawsuits allege that Bard knew or should have known about the dangers and risk of problems with its synthetic mesh but the company continued to market and promote the product as a safe and effective treatment for POP, while minimizing the risks of a Bard Avaulta procedure. Lawsuits claim that Bard failed to adequately research the product and establish that it provides both long term and short term efficacy.
Bard, based in Georgia, manufactures, distributes, and markets numerous medical devices. Brand names of Bard’s transvaginal mesh patches include: Avaulta Plus™ BioSynthetic Support System; Avaulta Solo™ Synthetic Support System; Faslata® Allograft;Pelvicol® Tissue; PelviSoft® Biomesh’;Pelvitex™ Polypropylene Mesh
The FDA has received over a thousand reports of Bard Avaultacomplications associated with surgical mesh since 2005. Complications most frequently involve erosion through the vaginal epithelium (in 2010, more than 75,000 women had vaginal mesh surgery to repair POP, at least 10 percent of whom suffered mesh erosion that required surgery to remove the mesh within 12 months); extrusion; infection; hardening of the mesh; chronic pain, and damage to surrounding organs.
Further problems reportedly include bowel, bladder and blood vessel perforation during insertion. In some cases, patients have undergone follow-up surgery to correct these problems. Because of its design, which allows tissue infiltration, the Bard Avualta mesh makes removal of the mesh very dangerous and potentially life-threatening. Other patients underwent IV therapy, blood transfusions and drainage of their hematomas or abscesses.
Bayer Female Employee Discrimination Class Action Amended to Include Sales Representatives-
http://www.bigclassaction.com/lawsuit/bayer-employee-discrimination-class-action-sales.php – Newark, NJ:Just days after the one year anniversary of winning a $250 million verdict for female sales representatives at Novartis Pharmaceuticals Corporation, a nearly identical discriminationclass action has been filed on behalf of female sales representatives at Bayer HealthCare Pharmaceuticals.According to the amended complaint, there is an entirely new class of plaintiffs and an additional Bayer HealthCare Division now added to the case. The Amended Complaint adds two new Class Representatives — a sales representative and an employee at Consumer Care — to join the six Class Representatives who filed the original complaint in March of this year on behalf of themselves and a class of female managers in the United States under Title VII of the 1964 Civil Rights Act and New Jersey law on March 21, 2011 .
Female Sales Rep Files Discrimination Class Action Against Merck – Newark, NJ: A $100 million individual and class action suit has been filed in the US District Court for New Jersey against pharmaceutical giant Merck & Co., Inc. The action, filed by Sanford Heisler LLP, was brought by Kelli Smith on behalf of all female sales representatives at Merck. The lawsuit asserts that the company systematically discriminatesagainst its female and pregnant employees in assignment, promotion, advancement, and pay and retaliates against female employees in violation of Title VII of the US Civil Rights Act, the Lilly Ledbetter Fair Pay Act, the Family and Medical Leave Act and the New Jersey Law Against Discrimination. “Merck is a male-dominated workplace openly hostile to the success and advancement of women,” said David Sanford, Founder and Chairman of Sanford Heisler and lead attorney on Ms. Smith’s legal team. “Its discrimination against mothers is particularly egregious because Merck’s compensation structure decreases the pay of managers whose subordinates take maternity leave.” Ms. Smith’s lawsuit details a widespread pattern of employment discrimination. Merck discourages management from hiring and promoting women, attempts to force pregnant women to leave the company so their managers’ compensation will not be affected, and structures compensation so that managers and colleagues of pregnant women get paid less because they work with women who take maternity leave.http://www.bigclassaction.com/lawsuit/female-sales-rep-discrimination-class-action-merck.php
Melnick Sisters Reach Settlement in Eli Lily DES Lawsuit
Boston, MA: A potential settlement has been reached between four sisters and the drug company Eli Lily, which could end the women’s lawsuit that alleges the diethylstilbestrol (DES) they were exposed to in the womb caused them to develop breast cancer. Between 1940 and 1971, DES was commonly used to prevent miscarriage and other pregnancy compl…http://www.lawyersandsettlements.com/search.html?keywords=male+lawsuits&page=11
Firm Admits Birth Control Pill Mixup
July 02, 1998|By From Tribune News Services.
SAO PAULO, BRAZIL — A Germanpharmaceuticalgroup acknowledged Wednesday making mistakes in a birth control pill mixup that allegedly left at least 11 Brazilian women pregnant. The drug group, Schering AG, said it would compensate the victims.
Two metric tons of placebo pills may have made their way to Brazilian consumers after disappearing from either Schering’s plant or an incineration facility in January, officials said.
Survey finds many NIH scientists also hired by drug firms
December 08, 2003By David Willman, Tribune Newspapers: Los Angeles Times.
BETHESDA, Md. — Subject No. 4 died at 1:44 a.m. on June 14, 1999, in the immense federal research clinic of the National Institutes of Health.
The cause of Jamie Ann Jackson’s death was clear: a complication from an experimental treatment for kidney inflammation using a drug made by the German company Schering AG.
Among the first to be notified about the 42-year-old patient’s death was Dr. Stephen Katz, the senior NIH official whose institute conducted the study.
“Science should be for the sake of gaining knowledge and looking for the truth,” said Dr. Curt Furberg, former head of clinical trials at the National Heart, Lung and Blood Institute. “There should be no other factors involved that can introduce bias on decision-making.”
German glass ceiling is thick, experts say (interesting) germany not women friendly!
April 10, 2002|By Nora FitzGerald. Special to the Tribune.
BERLIN — More than 3,000 of the 8,000 employees at Schering AG, a German pharmaceuticals company in Berlin, are women. Not one of them has reached the management board, called the Vorstand. Nor are there any women on its advisory council.
The glass ceiling is secure at Schering, just as it is in almost every German company, according to middle-level female executives and social scientists.
“Women have to fight for lead positions,” said Reinhild Engel, an equal opportunity official at Schering. “We have to change the company culture and the social culture.
Actavis to sell generic Yaz birth control after ruling Livlihoods
April 16, 2013|Reuters
WASHINGTON (Reuters) – Pharmaceutical company Actavis Inc said on Tuesday that it would once again sell a generic version of Bayer AG’s Yaz after an appeals court ruled that Bayer’s patent for the oral contraceptive was invalid.
The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday that a U.S. District Court in Nevada erred last March in finding the patent to be valid. It reversed the ruling.
Yaz is a reformulated version of Yasmin and remains one of the top-selling contraceptives in the United States. Actavis said that U.S. sales of Yaz, both branded and generic, were about $347 million annually.
Bayer’s Yasmin brand has been controversial. In 2012, Bayer agreed to pay a combined $400 million to settle almost one third of about 6,000 legal claims in the United States that Yasmin caused blood clots.
In April 2012, the FDA added information to the labels on Bayer’s Yaz and Yasmin, as well as others, to show they may raise the risk of blood clots.
All common birth control pills increase the chances of potentially fatal blood clots, but the FDA said the danger may be greater for more recent pills that contain the synthetic hormone drospirenone.
The cases at the Federal Circuit are: Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals Inc. and Sandoz Inc. (Case Nos. are 2012-1397, -1398, -1400) and Bayer Schering Pharma AG v. Watson Pharma and Lupin, Ltd. (Case No. 2012-1424.)
(Reporting by Diane Bartz in Washington and Bill Berkrot in New York; Editing by Andrew Hay and Leslie Adler)
Baby Boom Forces Brazil To Confront Fake Medicines
July 14, 1998|By Laurie Goering, Tribune Foreign Correspondent.
RIO DE JANEIRO — After undergoing uterine surgery, Valquiria Carvalho had strict orders from her doctor not to become pregnant. He recommended birth control pills and prescribed Brazil’s most popular brand, Microvlar.
Brazil is fighting back. This month the country stepped up an unprecedented crackdown on fraudulent medication after one of the highest-profile scams in years, the release of the batch of placebo birth-control pills as the real thing.
In January and February the Schering company of Brazil, a subsidiary of German pharmaceutical giant Schering AG, tested a new packaging machine on its Microvlar production line.
Flour substituted in the tests for the drug, one of Brazil’s most popular, with 1.8 million users annually. At the end of the testing, more than a ton of packaged pills and other leftovers from the testing process were shipped to an incinerator to be destroyed.
Feb 29, 2008, 9:07am EST
Bayer ’07 profit rises
Bayer AG profit nearly tripled in 2007 on strong sales of pharmaceuticals, the company said Thursday.
The rise was attributed in part to the purchase in 2006 of German rival Schering AG, which gained Bayer the Betaseron multiple sclerosis treatment.
Profit rose to $7.1 billion in 2007, up from $2.6 billion in 2006. Earnings per share rose from $3.36 to $8.86. Company revenue was up 12 percent to $49 billion.
However, fourth-quarter net income dropped 78 percent, year-over-year to $101.2 million, due to one-time expenses, including the integration of Schering.
Bayer has its North American headquarters in the Pittsburgh suburb of Robinson Township, where it employs about 1,500.
Sep 24, 2007, 8:55am PDT UPDATED: Sep 24, 2007, 1:31pm PDT
Sonus breast cancer drug fails key trial
Sonus Pharmaceuticals Inc. said that its Tocosol Paclitaxel breast cancer drug failed in a phase 3 pivotal trial and as a result, the drug won’t be submitted to the Food and Drug Administration for approval.
The news was crushing to the Bothell biotech (NASDAQ: SNUS), which raised $17.8 million in August 2005 to pay for the drug trial. Shares in Sonus plummeted nearly 84 percent in Monday trading, dropping $3.65 to close at 70 cents.
“We are profoundly surprised and disappointed that Tocosol Paclitaxel did not achieve the primary endpoint of this pivotal trial, particularly given the efficacy and safety results from previous clinical studies of our drug,” said Michael Martino, president and CEO of Sonus, in a statement.
Bayer grabs Emeryville site to protect top-selling drug In a move to safeguard its top-selling drug, Bayer AG will take control of a former ChironCorp. production facility in Emeryville, making Bayer the Bay Area’s second-largest biotech employer . It is the second time in 17 months that the facility that produces Bayer’s injected multiple sclerosis drug Betaseron has changed hands, assuming the U.S. Food and Drug Administration approves the changeover. And it comes as Betaseron’s patent protection nears expiration. Bayer is locking in production and royalties fromNovartis AG, which is selling the former Chiron facility and launching its own version of the drug. The deal, with points still being negotiated, allows Bayer’s Berkeley biotech subsidiary, Bayer HealthCare Pharmaceuticals, to add 550 people, and gives Bayer greater control over its Betaseron business, which had second-quarter sales of $353.7 million. “This is a different environment, but it’s still an exciting opportunity,” said Alfred Merz, who heads Bayer’s Emeryville transition team. “It’s really forward-looking.” As Novartis brings its version of Betaseron to the market in 2009, Bayer will produce it, shed the royalties it currently makes to Novartis, and, instead, receive royalties from the Swiss drug giant.
Bayer, says Michael Schuppenhauer, a biotech consultant in Half Moon Bay, must prove it has the attention span to build a strong biotech business. Bayer doesn’t appear to know its long-term strategy, he said. “Bayer has a lot of strategic decisions to make and a lot to do in their pipeline to be a serious, good biotech player,” he said.
Meanwhile, Novartis is expected eventually to market an oral multiple sclerosis drug that could be made elsewhere, whittle Bayer’s MS drug market share and Bayer’s Betaseron royalty receipts. Plus, other companies – including Alameda’s Pepgen Corp. and Palo Alto’s Bayhill Therapeutics Inc., both of which have products in Phase 2 clinical testing – are working on new-generation drugs for an MS market valued by drug-development companies at more than $5 billion. At the same time, Bayer is digesting last year’s acquisition of Schering AG, and rumors have surfaced that Novartis is targeting Bayer as a merger target.
Novartis Vaccines & Diagnostics took control of the Emeryville site with the purchase last year of Chiron. That triggered a provision that allowed Schering – and ultimately Bayer – to take over the section of the complex that produces Betaseron. Novartis will continue to occupy 90 percent of that complex. Upon leasing the Betaseron facility to Bayer, Novartis will employ about 1,200 people in the Bay Area. Chiron had 2,400 local employees when Novartis bought it in 2006.
Jun 19, 2007, 3:06pm EDT
Bayer raises projections
Bayer AG raised its profit forecast for the next three years, in part due to the acquisition of Schering AG.
The German drug company increased its profit margin estimate to more than 20 percent this year, from 19 percent previously, saying the Schering purchase will allow it to cut costs by $134 million more than forecast.
Bayer Corp. has its U.S. headquarters in Robinson Township, outside Pittsburgh.
Mar 15, 2007, 12:49pm EDT
Bayer profit surges
Bayer AG, Germany’s largest drugmaker, said fourth-quarter profit surged almost sevenfold, propelled by revenue from a multiple sclerosis treatment and birth-control pills gained in the purchase of rivalSchering AG.
Net income increased to $411 million, or 41 cents a share, compared to nearly $60.9 million in the same period a year ago.
Fourth quarter revenue totaled $10.5 billion in 2006, up 25 percent from the $8.4 billion the company reported in the 2005 fourth quarter.
Sales in North America advanced by 19.8 percent in 2006. In this region, improvements were recorded by HealthCare, thanks to strong sales in the Consumer Health segment, as well as by MaterialScience in the Polyurethanes business unit and in Coatings, Adhesives, Sealants.
Bayer’s Failure to Warn
Failure to warn is a legal term in tort law. It holds product manufacturers, suppliers, distributors, and retailers responsible for any injuries that may have been directly caused by their products. Under the failure to warn tort, parties associated with a product’s manufacturing and distribution have failed to emphasize a product’s inherent dangers to the public.
Bayer’s Deceptive Advertising
In addition to failure to warn claims, plaintiffs argue that Bayer’s advertising for Mirena was misleading. The advertising tactics allegedly misrepresented the benefits that Mirena could provide to its users. The advertising also concealed harmful side effects that resulted from Mirena use. Mirena complications can lead to serious injuries, surgery, infertility, and possible death! http://www.mirenalawsuit2013.com/mirena-lawsuits/
Risks Associated with Migration
The IUD can puncture and pass through the uterine wall, allowing it to travel to other parts of the body and cause serious internal injuries, such as:
abscesses, damage to internal organs, ulcers, embedment in the uterus, – dystrophic calcifications, infertility, Hysterectomy, inflammation of the membrane lining the abdominal cavity (peritonitis), Lymph Node Swelling, intestinal perforations or obstruction, ovary/fallopian tube damage – endometrium, hyperplasia, PID, hair loss, and loss of libido. The complications from the Mirena IUD also have resulted in infections, which could be potentially life threatening –Continuous Abnormal Paps
Bayer’s cost-cutting medicine is helping cure an entrepreneurial itch for one of its longtime executives.
Wolf Busse, a 28-year veteran of the German drugmaker, started ACT Biotech Inc. in late April to develop and market oral cancer drugs from more than 300 compounds licensed from Bayer HealthCare LLC. That includes a Phase II compound that could net a cancer drug as early as 2013.
The licensing deal, on top of $12 million in early venture capital financing, comes as Bayer continues to digest its 2006 purchase ofSchering AGfor $20 billion. Bayer, wanting to shed more than $900 million in combined annual costs, will close its West Haven, Conn., research facility and unload many of the drugs that were under development there. Busse opened the facility as Bayer’s first R&D operation in the United States.
Busse and Mahoney worked together at Bayer, including building a partnership with Onyx Pharmaceuticals Inc.of Emeryville on a compound that would become the cancer drug Nexavar. That drug also was a focus for Fattaey, who was vice president of research and development at Onyx for three years.
It’s the second time Busse has built a business on Bayer’s surplus compounds. He left Bayer in 2004 to start Aerovance as a respiratory and inflammatory drug development spinoff from Bayer compounds. That also came with the financial backing of NGN Capital.
It was NGN, which Busse joined as a venture partner after leaving Aerovance management in late 2005, that invested $12 million in the first tranche of ACT financing. Bayer has a 20 percent stake as well, and the Melanoma Therapeutics Foundation has a minority stake.
Meanwhile, Busse said the melanoma foundation and its mission is not lost. The foundation targets a cancer that will strike an estimated 62,000 people in the United States this year, killing more than 8,400.
Of the three or four compounds on which ACT is zeroing in on, the company has committed to developing at least one drug candidate for melanoma, Busse said. That would be an achievement, given that all potential melanoma treatments over the past decade have failed in late-stage clinical trials.
Negligence is historically a tort concept. With respect to product liability, manufacturers are liable for their failures to exhibit ordinary care to any party who suffered an injury that was proximately caused by that manufacturer’s negligent conduct. In what specific ways can a manufacturer be found negligent in conduct? There are five main ways, including through:
Design of the product = assembly and testing of a product = placement of inadequate warnings, labels, directions, or instructions on a product’s packaging, such that ordinary and average consumers and users are unaware of dangers or risks of harm associated with using the product –
Please Read Below Conspiracy – Bayer AG aka Bayer Healthcare akd Berlex aka Schering Impacting the American pharmaceutical Market
You will view the Int’l hidden pharmaceutical agenda with Europe-Germany infiltrating U.S. Markets
1979: Company is formed by Schering AG. – 1982:Berlex enters the imaging market.- 1988: Trademark suit settled with U.S.-based Schering Corporation. – 1990: Biotech Codon and Triton Biosciences acquired.
1997: Headquarters is moved to Montville, New Jersey.
Berlex Laboratories, Inc. is a Montville, New Jersey-based subsidiary of German pharmaceutical Schering AG. Berlex markets some 20 products, such as an oral contraceptive called Yasmin and medicines used to treatmultiple sclerosis, dermatological disorders, and cancer.The companyalso offers diagnostic imaging agents used in performing MRI scans. Berlex’s bioscience division is located in Richmond, California. Generating about $1.2 billion in annual sales, Berlex contributes about one-quarter of its parent corporation’s total revenues.
Although Berlex was founded in 1979, the roots of the company date back to the mid-19th century when Ernest Schering open a pharmacy in Berlin, Germany. He would incorporate the business in 1871 as Chemische Fabrik auf Actien and become involved in the production of chemicals, such as mercury compounds, that had uses in both pharmaceuticals and photography. In 1890, a year after Schering died,the company launched its first specialty product, a treatment for gout.
Over the next few decades,the company diversified into such areas as electroplating for decorative metals, industrial and laboratory chemicals, and agrochemicals. In the 1930s it merged with a mining and chemical company and the resulting entity was renamed Schering AG. From its earlier days,the companywas active in the United States. A subsidiary, Schering & Glatz, was launched in 1876 to distribute medicines produced by the parent company. However, 40 years later during World War I when the United States and Germany became enemies, the German-owned subsidiary was dissolved.
Schering returned to the U.S. market in 1929 by establishing New York City-basedScheringCorporation, a subsidiary that focused on hormone research and synthesized steroid drugs. When Germany and the United States were once again pitted against one another in World War II,the companycame under scrutiny, largely because itscorporateparent was suspected of working closely with the Nazis to produce drugs that might help German pilots to withstand the strains of high altitudes, thus giving them the tactical advantage of being able to fly higher. In 1942 Schering’s U.S. subsidiary was seized by the U.S. government, and some ten years later the government elected to sell the business to a private investment group headed by Merrill Lynch. As a result, the U.S.-based ScheringCorporationwas separated from Schering AG.
Schering AG struggled to rebuild its business during the difficult conditions that prevailed following the war.The companyused its expertise in steroids to produce the first birth control pill, simply known as “the Pill,” introduced to the European market in 1961. With the profits from this product, Schering was able to diversify and one again try the U.S. market. In 1972 it acquired a half-interest in New Jersey-based Knoll Pharmaceutical, the first of several acquisitions Schering would make in the United States over the next several years.
In 1990 Schering entered the U.S. biotechnology sector by acquiring two San Francisco-area companies: Triton Biosciences and CodonCorporation. A subsidiary of Shell Oil Company, Triton pursued anti-cancer drugs. However, its increasing demands for more funding, without any viable products toshowfor all of its efforts, had convinced Shell that it would be better off concentrating on its core competency, and it willingly sold the biotech to Schering. Triton had an upside for Schering in that it had two products in clinical trials: Fludara, used in the treatment of refractory chronic lymphocytic leukemia, and Betaseron, a treatment formultiple sclerosis. Established by college professors, Codon raised money by hiring out the expertise of its personnel.
The California start-up mindset sometimes clashed with the sensibilities of the Germancorporateparent, the executives of which were more conservative by nature and believed the Americans were moving ahead on projects too quickly. To address this problem and forge better understanding between the two cultures, a work exchange program was established, allowing employees to spend up to one year at an assignment outside their home country.
Also in 1993, Berlex introduced Betaseron, a breakthrough in the treatment of multiple sclerosis developed in conjunction with Chiron Corporation. (The product was manufactured by Chiron and sold by Berlex.) A genetically engineered form of interferon, a protein produced by the body to fight viruses, Betaseron was the first medication developed that could reduce the number of spikes in the disease, which could greatly worsen such symptoms as tremors, fatigue, and numbness. The drug Climara, a patch, was another first for Berlex when it was launched in 1995. Climara was the first transdermal estrogen replacement therapy product. The seven-day patch delivered estrogen to women directly into the blood stream, especially useful in the prevention of osteoporosis.
Betaseron – http://www.bigclassaction.com/lawsuit/betaseron.php – Betaseron (interferon beta-1b) is a medication approved by the FDA for the treatment of relapsing forms of Multiple Sclerosis, as a therapy to reduce the frequency of symptomatic exacerbations. Berlex, Inc., the manufacturer of the medication, recently contacted healthcare professionals to remind them about certain aspects of the prescribing information for Betaseron as it relates to liver toxicity.
Bayer Warns Betaseron Packaged With Recalled Alcohol Prep …–http://www.aboutlawsuits.com/betaseron-prep-pad-warning-15709 – Jan 21, 2011 · Bayer Healthcare Pharmaceuticals is warning consumers and doctors thatBetaseron, a multiple sclerosis medication, was shipped with recalled alcohol prep p
Climara Pro®(estradiol/levonorgestrel patch) is a prescription estrogen and progestin hormone replacement medication. It is approved for the following uses – Generic Climara Pro
There is currently no generic Climara Pro approved in the United States. A patent prevents any generic versions of the medication from being made until at least 2014. However, certain circumstances could come up that would delay or speed up the availability of generic Climara Pro, such as lawsuits or other patents for specific uses. healthquestions.medhelp.org/climara-lawsuits
VERY DISTURBING WOMEN OF AMERICA:
Information About Ethinyl Estradiol and Yaz Lawsuit – http://howdrugs.com/information-about-ethinyl-estradiol-and-yaz-lawsuit/
Related posts: (Look how these corporations are intermingling chemicals)
Please continue reading more Berlex Information acquired by Bayer AG aka Bayer Healthcare: Additional pharmaceutical conspiracies in America
In the final years of the 1990s, Berlex moved to new headquarters in Montville, New Jersey, and introduced several new products. It launched Levlite in 1998, an oral contraceptive with a lower dosage than Levlen. In 1999 Climara became available in a new low-dose form. Another new Berlex drug, also launched in 1999, was Quadramet, used to treat the pain that accompanied metastatic bone cancer. In addition, Berlex acquired two new diagnostic imaging products in 1999: Acutect and Neotect.
Cytogen, DuPont Merck End Quadramet Agreement.(pain killer–http://www.highbeam.com›Chemical Week ›June 1998 Jun 17, 1998· Biopharmaceutical maker Cytogen says it has ended a licensing agreement with DuPont Merck for… | Article from Chemical Week June 17, 1998
QUADRAMET(TM) NEW DRUG APPLICATION FILED BY FDA – http://www.thefreelibrary.com/QUADRAMET(TM)+NEW+DRUG+APPLICATION+FILED+BY+FDA-a017145077
History of Berlex Laboratories, Inc. –FundingUniverse – www.fundinguniverse.com/company-histories/berlex-laboratories-inc……Acutectand Neotect. … “Bogen to Pay $55 Million in Deal To Settle Schering PatentLawsuit,” Wall Street Journal, February 4, 2003, p. B7. Sellers, …
2001 Berlex launched five products: Campath, used to treat B-cell chronic lymphocytic leukemia; Refludan, a thrombin inhibitor used to treat patients with heparin-induced thrombocytopenia and associated thromboembolic disease; Finevin, an acne medication; Mirena, an implanted contraceptive; and Yasmin, an oral contraceptive. Additionally in 2001 Berlex acquired Refludan, a direct thrombin inhibitor used to treat patients with heparin-induced thrombocytopenia. A year later Berlex acquired Leukine, prescribed for older adults with acute myelogenous leukemia following chemotherapy, after bone marrow transplantation, or peripheral blood stem cell transplantation. In 2003 Berlex introduce Finacea, a topical treatment for rosacea.
CampathLawsuitdoihavealawsuit.com/…/234-campath–lawsuit.html Campath Lawsuit Campath Side Effects Campath is an alemtuzumab injection for intravenous use. Campath (alemtuzumab) is a recombinant DNA-derived humanized …
Acne Therapies. (Drugs, Pregnancy, and Lactation) – Topical and systemic agents are used in the treatment and prevention of acne, ranging from those that have negligible risks during pregnancy to a drug that is a major teratogen. Azelaic acid (Azelex, Finevin), a topical antimicrobial, agent, is rated pregnancy risk factor B. It is embryotoxic in animals, but only at maternal toxic doses http://www.thefreelibrary.com/Acne+Therapies.+(Drugs%2c+Pregnancy%2c+and+Lactation).-a098830100
PLEASE DO YOU DUE DILIGENCE AMERICA MEN AND WOMEN BEFORE TAKING ANY PHARMACEUTICAL DRUG OR IT MAY COST YOU, YOUR LIFE!! THIS ARTICLE WAS PRODUCED FOR EDUCATIONAL PURPOSES ONLY TO HELP SAVE AMERICAN LIVES!
Women Are Paid Less Than Men Not Because of Discrimination https://www.youtube.com/watch?v=IMkDEe8ypfU
News Update: Novartis Loses Gender Discrimination Lawsuit https://www.youtube.com/watch?v=4Vjuwgbv5jc
Sexual Discrimination, Maternity Leave and Hostility, and a Large Legal Settlement https://www.youtube.com/watch?v=UfCh5RCDg9M
Gender Discrimination at Job Interview https://www.youtube.com/watch?v=Eb-AqnwOTxE
Federal Judge Reveals Judicial Corruption https://www.youtube.com/watch?v=SPXfYWKFME8
“ALEC (American Legislation Exchange Council) Protest at Westin Kieland Resort” pt.1 of 2 https://www.youtube.com/watch?v=QcNeojyMZ7I
Drugs, Money and Power: Big Pharma – STDWYTK – https://www.youtube.com/watch?v=l5qhvfMRHqI
Making a Killing: The Pharmaceutical Industry Pt 1/3 – https://www.youtube.com/watch?v=5sjajVVEzoE
Bill Schnoebelen – The Medical Conspiracy https://www.youtube.com/watch?v=GSQwS1Hf0yE
ALEX JONES dénonce la conspiration de big pharma https://www.youtube.com/watch?v=uoRh9jsL6Wo
Population Controls, Eugenics, Root Race Theory & Social-Spiritual-Racial Evolution – https://www.youtube.com/results?search_query=Eugenics+Theory&sm=3
Goverment Eugenics Program – https://www.youtube.com/watch?v=U_uO8fW5dsQ
Victims of a eugenics sterilization program in North Carolina speak out – https://www.youtube.com/watch?v=0exeyPb5BiA
Eugenicist Movement in America: Victims Coming Forward – https://www.youtube.com/watch?v=Nshj9rCTPdE
Sex Control Police State, Eugenics, Galton, Kantsaywhere, Mind Control Report https://www.youtube.com/watch?v=8_l6gbgzwRY
EUGENICS U.K. – Elderly & Disabled Cut Out Of Social Care System https://www.youtube.com/watch?v=wkPjDcflPCc
D.O.V.E. Research BIRTH CONTROL EUGENICS https://www.youtube.com/watch?v=SCvhDRMbjNI
Web Content Freelance Writer & Corporate Research